$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색도움말
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"

통합검색

도움말도움말
상세검색 다국어 입력

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

특허 상세정보

MyON담기
내보내기 페이스북 공유 카카오톡 공유

Methods of treating Crohn's disease or ulcerative colitis using an induction dosing regimen comprising anti-TNF-alpha antibody

특허상세정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판) A61K-039/00    C07K-016/24   
출원번호 US-0564677 (2016-04-08)
등록번호 US-10179811 (2019-01-15)
우선권정보 EP-15163277 (2015-04-10); EP-15163775 (2015-04-15)
국제출원번호 PCT/EP2016/057847 (2016-04-08)
국제공개번호 WO2016/162537 (2016-10-13)
발명자 / 주소
  • Moodie, Rachel
  • Hyland, Elizabeth
출원인 / 주소
  • Fresenius Kabi Deutschland GmbH
대리인 / 주소
    Goodwin Procter LLP
인용정보 피인용 횟수 : 0  인용 특허 : 67
초록

The invention relates to a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNFα antibody which ranges from 161 to 320 mg such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs.

대표
청구항
▼

1. A method of treating Crohn's disease or ulcerative colitis, the method comprising administering a multiple-variable dose to a subject in need thereof comprising administering a first induction dose of an anti-TNFα antibody in the amount of 161 to 320 mg such that a threshold level of the anti-TNFα antibody is achieved within an induction phase; administering a second induction dose of the anti-TNFα antibody in the amount of 80 to 160 mg subsequent to the first induction dose; and administering at least one treatment dose of the anti-TNFα antibody for ...

인용문헌 (67)

  1. Fraunhofer, Wolfgang; Bartl, Annika; Krause, Hans-Juergen; Tschoepe, Markus, Anti-TNF antibody formulations.
  2. Fraunhofer, Wolfgang; Bartl, Annika; Krause, Hans-juergen; Tschoepe, Markus; Kaleta, Katharina, Antibody formulations and methods of making same.
  3. Julian, Joseph F.; Rolfe, Steven; Bicknell, Stephen; Marshall, Jeremy, Automatic injection device.
  4. Julian, Joseph F.; Rolfe, Steven; Bicknell, Stephen; Marshall, Jeremy, Automatic injection device.
  5. Julian, Joseph F.; Rolfe, Steven; Bicknell, Stephen; Marshall, Jeremy, Automatic injection device.
  6. Stuhlmüller, Bruno; Burmester, Gerd-Reudiger, Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders.
  7. Trollsas, Mikael; Stankus, John; Su, James; Hossainy, Syed; Smith, Joshua Takeshi; Askar, Shadid, Delivery of biologic therapeutics.
  8. Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.; Salfeld, Jochen G., Dual variable domain immunoglobulin and uses thereof.
  9. Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.; Salfeld, Jochen G., Dual variable domain immunoglobulin and uses thereof.
  10. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  11. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  12. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  13. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  14. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  15. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  16. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  17. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  18. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  19. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  20. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  21. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  22. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-alpha associated disorders.
  23. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  24. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  25. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  26. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  27. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  28. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  29. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  30. Krause, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  31. Kruase, Hans-Juergen; Baust, Lisa; Dickes, Michael, Formulation of human antibodies for treating TNF-α associated disorders.
  32. Neu, Michael; Tschoepe, Markus; Weber, Carsten; Fraunhofer, Wolfgang; Redden, Laura; Gastens, Martin; Feick, Alexander, High concentration anti-TNFα antibody liquid formulations.
  33. Kaymakcalan, Zehra; Kamen, Robert, Low dose methods for treating disorders in which TNFα activity is detrimental.
  34. Wong, Robert L.; Kupper, Hartmut; Medich, John R., Method of treating ankylosing spondylitis.
  35. Maksymowych, Walter P.; Wong, Robert L., Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers.
  36. Maksymowych, Walter P.; Wong, Robert L., Methods and compositions for diagnosing ankylosing spondylitis using biomarkers.
  37. Okun, Martin M.; Hoffman, Rebecca S.; Barker, Jonathan, Methods and compositions for treatment of skin disorders.
  38. Kupper, Hartmut; Kent, Jeffrey D.; Cifaldi, Mary A.; Perez, John L.; Burmester, Gerd R.; Mease, Philip; Lovell, Daniel J.; Keystone, Edward; Kavanaugh, Arthur, Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis.
  39. Medich, John R.; Paulson, Susan K.; Noertersheuser, Peter A., Methods for treating juvenile idiopathic arthritis.
  40. Medich, John R.; Paulson, Susan K.; Noertersheuser, Peter A., Methods for treating juvenile idiopathic arthritis.
  41. Medich, John R.; Paulson, Susan K.; Noertersheuser, Peter A., Methods for treating juvenile idiopathic arthritis by inhibition of TNFα.
  42. Wong, Robert L.; Kupper, Hartmut; Luo, Michelle P.; Sieper, Joachim; Davis, John C.; Maksymowych, Walter P., Methods for treatment of ankylosing spondylitis using TNF alpha antibodies.
  43. Fischkoff, Steven A.; Kempeni, Joachim; Weiss, Roberta, Methods of administering anti-TNFα antibodies.
  44. Fischkoff, Steven A.; Kempeni, Joachim; Weiss, Roberta, Methods of administering anti-TNFα antibodies.
  45. Fischkoff, Steven A.; Kempeni, Joachim; Weiss, Roberta, Methods of administering anti-TNFα antibodies.
  46. Fischkoff, Steven A.; Kempeni, Joachim; Weiss, Roberta, Methods of administering anti-TNFα antibodies.
  47. Fischkoff, Steven A.; Kempeni, Joachim; Weiss, Roberta, Methods of administering anti-TNFα antibodies.
  48. Fischkoff, Steven A.; Kempeni, Joachim; Weiss, Roberta, Methods of administering anti-TNFα antibodies.
  49. Fischkoff, Steven A.; Kempeni, Joachim; Weiss, Roberta, Methods of administering anti-TNFα antibodies.
  50. Okun, Martin M.; Harris, Thomas C., Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies.
  51. Okun, Martin M.; Harris, Thomas C., Methods of treating moderate to severe hidradenitis suppurativa with anti-TNFalpha antibody.
  52. Hoffman, Rebecca S.; Chartash, Elliot K.; Taylor, Lori K.; Granneman, George R.; Yan, Philip, Multiple-variable dose regimen for treating TNFα-related disorders.
  53. Hoffman, Rebecca S.; Chartash, Elliot Keith; Taylor, Lori K.; Granneman, George Richard; Yan, Philip, Multiple-variable dose regimen for treating TNFα-related disorders.
  54. Hoffman, Rebecca S.; Chartash, Elliot Keith; Taylor, Lori K.; Granneman, George Richard; Yan, Philip, Multiple-variable dose regimen for treating TNFα-related disorders.
  55. Hoffman, Rebecca S.; Chartash, Elliot K.; Taylor, Lori K.; Granneman, George R.; Yan, Philip, Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease.
  56. Hoffman, Rebecca S.; Chartash, Elliot K.; Taylor, Lori K.; Granneman, George R.; Yan, Philip, Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease.
  57. Hoffman, Rebecca S.; Chartash, Elliot K.; Taylor, Lori K.; Granneman, George R.; Yan, Philip, Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease.
  58. Fraunhofer, Wolfgang; Bartl, Annika; Krause, Hans-Juergen; Tschoepe, Markus; Kaleta, Katharina, Protein formulations and methods of making same.
  59. Hoffman, Rebecca S.; Weinberg, Mark, Use of TNF alpha inhibitor for treatment of erosive polyarthritis.
  60. Banerjee, Subhashis; Hoffman, Rebecca S.; Weinberg, Mark; Taylor, Lori K.; Spiegler, Clive E.; Tracey, Daniel E.; Chartash, Elliot K.; Barchuk, William T.; Yan, Philip; Murtaza, Anwar; Salfeld, Jochen G.; Fischkoff, Steven A.; Granneman, George R., Use of TNF-alpha inhibitor for treatment of psoriasis.
  61. Hoffman, Rebecca S.; Weinberg, Mark; Taylor, Lori K.; Chartash, Elliot K.; Yan, Philip; Granneman, George R., Use of TNFα inhibitor.
  62. Hoffman, Rebecca S.; Weinberg, Mark; Banerjee, Subhashis; Taylor, Lori K.; Spiegler, Clive E.; Tracey, Daniel E.; Chartash, Elliot K.; Barchuk, William T.; Yan, Philip; Murtaza, Anwar; Salfeld, Jochen G.; Fischkoff, Steven A.; Granneman, George R., Use of TNFα inhibitor for treatment of psoriasis.
  63. Hoffman, Rebecca S.; Weinberg, Mark; Taylor, Lori K.; Chartash, Elliot K.; Yan, Philip; Granneman, George R., Use of TNFα inhibitor for treatment of psoriasis.
  64. Hoffman, Rebecca S.; Weinberg, Mark, Use of TNFα inhibitor for treatment of psoriatic arthritis.
  65. Hoffman, Rebecca S.; Weinberg, Mark; Banerjee, Subhashis; Taylor, Lori K.; Spiegler, Clive E.; Tracey, Daniel E.; Chartash, Elliot K.; Barchuk, William T.; Yan, Philip; Murtaza, Anwar; Salfeld, Jochen G.; Fischkoff, Steven A.; Granneman, George R., Use of TNFα inhibitor for treatment of psoriatic arthritis.
  66. Hoffman, Rebecca S.; Weinberg, Mark, Use of human TNFα antibodies for treatment of erosive polyarthritis.
  67. Medich, John R.; Wong, Robert L.; Perdok, Renee J.; Sasso, Eric H.; Hoffman, Rebecca S.; Mease, Phillip; Ritchlin, Christopher T., Uses and compositions for treatment of psoriatic arthritis.

IPC 상위 출원인